Article Text

Download PDFPDF

Adjuvant and neoadjuvant therapies in melanoma
  1. Kok Haw Jonathan Lim1,
  2. Teresa Amaral2
  1. 1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
  2. 2Interdisciplinary Skin Cancer Centre, University Medical Centre Tuebingen, Tuebingen, Germany
  1. Correspondence to Dr Kok Haw Jonathan Lim; jonathan.lim{at}doctors.org.uk
  • Podcast
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

The therapeutic landscape in melanoma is evolving rapidly. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews Dr Teresa Amaral (the current chair of the ESMO Young Oncologists Committee and an expert in melanoma) for an update on the current practice and advances in adjuvant and neoadjuvant therapies in melanoma.

Dr Amaral summarises key practice-changing studies which have established the current recommendations in this field, including CheckMate 238, KEYNOTE 054, COMBI-AD, Combi-Neo, NeoCombi and opACIN-neo. We also deliberated on the toxicity profile of these therapies, and currently available evidence of neoadjuvant versus adjuvant therapies. Finally, we addressed how COVID-19 has affected the delivery of adjuvant and neoadjuvant therapies in patients with melanoma.

View Abstract

Footnotes

  • Funding The authors have not declared a specific grant for this particular research from any funding agency in the public, commercial or not-for-profit sectors. KHJL is currently funded by the Wellcome Imperial 4i Clinical Research Fellowship.

  • Competing interests TA receives personal fees and travel support from Bristol-Myers Squibb and Novartis, and personal fees from Pierre Fabre and CeCaVa.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.